The combination of lapatinib plus trastuzumab for patients with metastatic HER2-positive breast cancer resulted in high response rates when used early. Additionally, undergoing [18F]fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG-PET/CT) 1 week into therapy could predict response to this treatment. {read more here}